Citations

Clear

4201 citation(s) found for "Chen, C".

Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression
O'Hara, Steven P. , Bogert, Pamela Tietz, Dickinson, Stephanie, Chen, Xiwei , Netto, Jair Machado Espindola, Kirkland, James L., Tchkonia, Tamara, Ashraf, Humza M. , Morgenthaler, Olivia , Ali, Ahmad H. , Gores, Gregory J., LaRusso, Nicholas, O’Hara, Steven P. , Bogert, Pamela S., Dickinson, Stephanie, Allison, David B. , Espíndola‐Netto, Jair Machado , Kirkland, James L. , Tchkonia, Tamar , Lazaridis, Konstantinos N. , Gores, Gregory J. , LaRusso, Nicholas F.

Mayo Clinic

Journal of Gastroenterology and Hepatology | February 14, 2026 | Volume: 41 | Issue: 3 | Pages: 1065-1076

10.1111/jgh.70279 | PMID 41689244 Get It

ABSTRACT Background and Aims Cellular senescence is a hallmark of several liver diseases, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Senescent cholangiocytes exhibit a senescence‐associated secretory phenotype (SASP), characterized by profibroinflammatory mediator release. Current cost‐effective biomarkers predicting disease progression, particularly for PSC, are limited and often lack mechanistic relevance. We sought to define a plasma biomarker signature for PSC and PBC. Methods Plasma from early‐ and late‐stage PSC and PBC, alcoholic liver disease (ALD), inflammatory bowel disease (IBD) patients, and healthy controls was analyzed. Seventy‐one analytes were quantified using Luminex Multiplex Immunoassay or enzyme‐linked immunosorbent assay (ELISA). Principal component analysis (PCA) identified key patterns. Findings from the PSC cohort were then applied to additional cohorts. Results Second principal component (PC2) (17 analytes, 17.1% variability) best separated PSC from controls. ANOVA showed significant differences in PC2 between early PSC vs. controls ( p = 0.0001), late PSC vs. controls ( p < 0.0001), and early vs. late PSC ( p < 0.0001). PC2 analytes also distinguished early PBC vs. controls ( p < 0.0332), late PBC ( p < 0.0001), and ALD ( p < 0.0001), and early vs. late PBC ( p < 0.0001), but not IBD vs. controls ( p = 0.119). Logistic regression using PC2 demonstrated strong discrimination of early‐ and late‐stage PSC (AUC = 0.86) and control vs. early‐stage PSC (AUC = 0.83). Conclusion This is the first study to define a plasma SASP biomarker signature associated with cholestatic liver disease. These analytes track disease stage and represent both mechanistic indicators and potential clinical trial endpoints.
Uncharted Territory: Retrospective Comparison of Care Pathways for Treatment of Female Pelvic Floor Myofascial Pain in a Tertiary Care Center
Neville, Cynthia E. , Chen, Anita H. , Thao, Viengneesee , Sacket, Anne M., Glasgow, Amy E. , Spaulding, Aaron , Tasman, Jordan , Carrubba, Aakriti R., Spaulding, Aaron , Hunt, Christine , Carrubba, Aakriti R.

Mayo Clinic

Journal of Women's & Pelvic Health Physical Therapy | February 12, 2026 | Volume: 50 | Issue: 2 | Pages: 137-148

10.1097/jwh.0000000000000353 Get It

Purpose: A variety of care pathways are offered to females with chronic pelvic pain (CPP) and pelvic floor myofascial pain (PFMP), which may affect treatment outcomes. This study aims to compare care pathways and describe health care utilization and characteristics of patients with CPP and PFMP referred for physical therapy (PT) at a tertiary care center. Methods: A retrospective cohort analysis was conducted on females with CPP and PFMP referred for PT. Patients received PT, medication management, injection therapy, or a combination of treatments. We collected data on health care utilization, comorbidities of interest, and patient-reported outcome measures (PROMs). Wilcoxon rank-sum tests were used to compare patients with pre- and posttreatment PROM scores. Results: A total of 1172 patients were referred for PT treatment, but 19.5% (n = 229) did not attend any PT sessions, and only 18% (n = 211) of patients attended the recommended number of PT sessions. Comorbid urinary (48.5%, n = 569) and bowel dysfunction (43%, n = 512) were prevalent. Patients consulted with multiple providers. Most patients (57.1%, n = 669) utilized opioid medications. Less than 20% completed both pre-and posttreatment PROMs. Discussion: Care pathways vary widely for the treatment of PFMP. Low adherence to PT and a trend toward greater than 5 subspecialty appointments indicating higher health care utilization reflect the range of inconsistent patient experience likely affecting outcomes. Outcomes of care are uncharted territory. Optimal care pathways for CPP and PFMP need to be established, along with further investigation of PROMs, to determine which treatments result in effective outcomes that matter to patients.
Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia
Lee, Jae Woong , Sun, Ruifeng , Kume, Kohei , Robinson, Mark E. , Cheng, Zhangliang, Cosgun, Kadriye Nehir , Ma, Ning , Hurtz, Christian , Geng, Huimin , Luger, S. M., MR, Litzow, Paietta, E, Vaidehi, Nagarajan , Müschen, Markus, Luger, Selina M. , Geng, Huimin , Lee, Jaewoong , Luger, Selina M , Litzow, Mark R. , Chen, Jianjun , Vaidehi, Nagarajan , Müschen, Markus , Müschen, Markus

Mayo Clinic

Science Signaling | February 10, 2026 | Volume: 19 | Issue: 924 | Pages: No page available

10.1126/scisignal.adw5054 | PMID 41666265 Get It

CD25 is a subunit of the interleukin-2 (IL-2) receptor on T cells and natural killer (NK) cells. Acute leukemias with oncogenic tyrosine kinases often include CD25 + leukemia subpopulations, which portend poor clinical outcomes for patients; however, acute leukemia cells do not respond to IL-2. Here, we identified CD25 and its phosphorylation by protein kinase Cδ (PKCδ) as central elements of a feedback loop that stabilized fluctuations in oncogenic tyrosine kinase signaling in acute lymphoblastic and myeloid leukemia. Genetic ablation of CD25 in murine and patient-derived xenograft (PDX) models of acute leukemias reduced clonal fitness, colony formation, and leukemia-initiation capacity in serial transplant recipients. Oncogenic tyrosine kinase signaling in leukemia cells stimulated NF-κB–mediated CD25 expression, whereas PKCδ-mediated phosphorylation of CD25 suppressed oncogenic tyrosine kinase signaling through inhibitory phosphatases, such as PTPN6. Interactome analyses and mass spectrometry–based global phosphoproteomic analyses showed that CD25 deletion abolished the phosphatase activity of PTPN6, resulting in enhanced activation of tyrosine kinases and NF-κB. Four injections of a CD25 antibody-drug conjugate induced complete remission in mice transplanted with PDX refractory leukemia. These findings highlight the dependency of tyrosine kinase–driven leukemias on robust feedback control and the role of PKCδ and CD25 in assembling its components.
Point of care molecular cancer diagnostics
Bhaskar, Seemesh , Umrao, Saurabh , Lee, Han Keun , Tibbs, Joseph , Bacon, Amanda , Shepherd, Skye , Ayupova, Takhmina , Ciloglu, Fatma Uysal , Liu, Leyang , Tan, Anqi , Chen, Wang-Chien , Nguyen, My Thi Tra , Scannell, Maria Grace , Aygün, Uğur , Zhang, Catherine, Adami, Guy R. , Badar, Wali, Gaba, Ron C. , Mansfield, A., Schwartz, Joel L., XING, WANG, Demirci, Utkan, Parlatan, Ugur , Zhang, Catherine , Kohli, Manish , Adami, Guy R , Badar, Wali , Gaba, Ron C , Mansfield, Aaron S , Schwartz, Joel , Xing, Wang , Demirci, Utkan , Cunningham, Brian T , Kohli, Manish , Mansfield, Aaron S. , Demirci, Utkan , Cunningham, Brian T.

Mayo Clinic

Lab on a Chip | February 10, 2026 | Volume: 26 | Issue: 10 | Pages: 2948-3001

10.1039/d5lc01014d | PMID 41811171 Get It

Convergent framework for future POC cancer diagnostics aligning clinical needs (why), enabling technologies (how), and translational bridges. It integrates lab-on-chip biosensing and analytics for decentralized, early, longitudinal care.
Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis optica model induced by subarachnoid AQP4-IgG
Qi, Fangfang, Lennon, Vanda A. , Zhao, Shunyi, Guo, Yong, Ding, Husheng, Liu, Caiyun, Bartley, Whitney M., Chen, Tingjun, Lucchinetti, Claudia F. , Wu, Long-jun, Wu, Long‐Jun , Guo, Yong , Wu, Long-Jun , Guo, Yong , Qi, Fangfang

Mayo Clinic

Journal of Clinical Investigation | February 10, 2026 | Volume: 136 | Issue: 7 | Pages: No page available

10.1172/jci199706 | PMID 41665955 Get It

Neutrophils and neutrophil extracellular traps (NETs) contribute to early neuromyelitis optica (NMO) histopathology initiated by IgG targeting astrocytic aquaporin-4 (AQP4) water channels. Yet, the mechanisms underlying neutrophil recruitment and their pathogenic roles in disease progression remain unclear. To investigate molecular-cellular events preceding classical complement cascade activation in a mouse NMO model, we continuously infused, via spinal subarachnoid route, a non-complement-activating mouse monoclonal AQP4-IgG. Parenchymal infiltration of netting neutrophils containing C5a ensued with microglial activation and motor impairment but no blood-brain barrier leakage. Motor impairment and neuronal dysfunction both reversed when AQP4-IgG infusion stopped. Two-photon microscopy and electron microscopy–based reconstructions revealed physical interaction of infiltrating neutrophils with microglia. Ablation of either peripheral neutrophils or microglia attenuated the motor deficit, highlighting their synergistic pathogenic roles. Of note, mice lacking complement receptor C5aR1 exhibited reduction in neutrophil infiltration, microglial lysosomal activation, neuronal lipid droplet burden, and motor impairment. Pharmacological inhibition of C5aR1 recapitulated this protection. Immunohistochemical analysis of an NMO patient’s spinal cord revealed disease-associated microglia surrounding motor neurons in nondestructive lesions. Our study identifies neutrophil-derived C5a signaling through microglial C5aR1 as a key early driver of reversible motor neuron dysfunction in the precytolytic phase of NMO.
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60

10.6004/jnccn.2026.0006 | PMID 41671432 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
AI-generated data contamination erodes pathological variability and diagnostic reliability
Liu, Dianbo, He, Hongyu , Xiang, Shaowen, Zhang, Ye, Zhu, Yingtao, Zhang, Jin, Lu, Yunyi, Deng, Hao , Alsentzer, Emily, Liu, Yun, Chen, Qingyu , Yu, Kun‐Hsing , Marshall, Andrew, Chen, Tingting, Anumasa, Srinivas, Ebner, Daniel, Ho, Dean , Cheng, Ching-Yu, Alsentzer, Emily , Yu, Kun‐Hsing , Ngiam, Kee Yuan , Cheng, Ching‐Yu

Mayo Clinic

No container title available | February 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8753102/v1 Get It

Abstract Generative artificial intelligence (AI) is rapidly populating medical records with synthetic or partially AI-generated content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological variability and diagnostic reliability of medical data at population scale. By analysing more than 800,000 synthetic data points across clinical text generation, vision–language reporting, and medical image synthesis, we find that models progressively converge toward generic phenotypes regardless of the model architectures. Specifically, rare but critical findings, including pneumothorax and effusions, vanish from the synthetic content generated by AI models, while demographic representations skew heavily toward middle-aged male phenotypes. Crucially, this degradation is masked by false diagnostic confidence. Models continue to issue reassuring reports while failing to detect life-threatening pathology, with false reassurance rates tripling to 40%. Blinded physician evaluation confirms that this decoupling of confidence and accuracy renders AI-generated documentation clinically useless after just two generations. We systematically evaluate three mitigation strategies that can be easily integrated into existing clinical workflows, finding that while synthetic volume scaling fails to prevent collapse, mixing real data with quality-aware filtering effectively preserves diversity. Ultimately, our results suggest that without policy-mandated human oversight, the deployment of generative AI threatens to degrade the very healthcare data ecosystems it relies upon.
Clinical Features and Dental Pathologies in Maxillary Sinus Fungal Balls and Odontogenic Sinusitis
Im, E., Donaldson, Lane , Adappa, Nithin D, Chen, Y. P., Chapurin, Nikita , Espinosa, Maria, Fu, Chia‐Hsiang , Fox, Meha G, Garg, Rohit, Kohanski, Michael A. , Li, Kevin L. , Liu, Duxuan , Locke, Tran Bao, Lin, Chih‐Feng, Ottavi, Alice, Papagiannopoulos, Peter , Je, Palmer, Tong, C., Tajudeen, Bobby A. , Venkatesh, Sanjena , Wei, Kimberly , Yoo, Frederick , Yu, Alison J. , Jin, Jun, Saibene, Alberto Maria , Craig, John, Im, Eunice , Douglas, Jennifer E , Eide, Jacob, Espinosa, Maria , Fox, Meha G , Locke, Tran Bao , Makary, Chadi , Venkatesh, Sanjena , Saibene, Alberto M , Adelman, Avraham E. , Adappa, Nithin D. , D’Souza, Glen , Eide, Jacob G. , Fox, Meha G. , Garg, Rohit , Kuan, Edward C , Kwiatkowska, Marta Aleksandra , Liu, Derek H., Locke, Tran B. , Jin, Jun

Mayo Clinic

The Laryngoscope | February 8, 2026 | Volume: 136 | Issue: 7 | Pages: 2913-2924

10.1002/lary.70429 | PMID 41654324 Get It

ABSTRACT Objectives While maxillary sinus fungal balls (MSFB) can be associated with odontogenic conditions (MSFBO), MSFBO clinical and dental features have not been compared to odontogenic sinusitis (ODS). This multicenter study aimed to compare characteristics of MSFB, MSFBO, and ODS. Methods A multicenter international retrospective cohort study was conducted on adults with MSFBs and ODS who underwent sinus surgery. First in MSFBs, it was determined whether different dental conditions were more likely in FB versus non‐FB sides. Second, clinical features and dental pathologies were compared between MSFBO and ODS. For analyses, dental conditions were considered individually and as two groups: infectious pathologies and dental/oral procedures with indwelling metallic materials. Results After exclusions, there were 203 MSFBs and 163 ODS. Among MSFBs, 141 were MSFBOs. FB sides were associated with sinus protrusion of root canal treatment (RCT) materials ( p = 0.040) and dental implants ( p = 0.040). Compared to MSFBO, ODS patients were younger, more likely to have MS purulence (OR = 40.9, p < 0.010), more likely associated with apical periodontitis (OR = 2.59, p = 0.010) and oroantral fistulas (OR = 6.94, p = 0.020), and less likely associated with extruded RCT materials (OR = 0.01, p = 0.010) and protruded midface screws (OR < 0.01, p = 0.010). Comparing purulent MSFBO and ODS, ODS was more associated with infectious dental pathologies ( p < 0.009). Conclusion Compared to MSFBs, MSFBOs were associated with RCT extrusion and implant protrusion. Compared to MSFBOs, ODS was more likely purulent and associated with infectious dental pathologies. While ODS is often distinct from MSFBO, the two conditions can coexist, and surgeons must determine whether patients have infectious dental pathology requiring treatment with both conditions. Level of Evidence 4.
High NKAP expression predicts poor prognosis of breast cancer patients
Li, Yonghao , Zheng, Shu , Sun, Chenyu, Lowe, Scott, Bentley, Rachel, Li, Yaru , King, Bethany, Chen, Shuya, Zhou, Qin, Zhang, Mei , Bentley, Rachel

Mayo Clinic

Medicine | February 6, 2026 | Volume: 105 | Issue: 6 | Pages: e47497

10.1097/md.0000000000047497 | PMID 41650063 Get It

NF-κB activating protein (NKAP) plays important roles in various cancers, including breast cancer. However, its expression and prognosis value in breast cancer remains uncertain. Gene expression profiling interactive analysis, Human protein atlas database, and University of Alabama at Birmingham Cancer data analysis portal database were used to predict the expression and prognostic value of NKAP in breast cancer. Immunohistochemistry, quantitative real time polymerase chain reaction (qRT-PCR) and western blot were performed to detect NKAP expression. The effects of NKAP on cell proliferation, migration and drug sensitivity were investigated in MDA-MB-231 and SK-BR-3 cells. NKAP protein expression differed in breast cancer tissues and paraneoplastic tissues based on the cancer genome atlas data. The high NKAP expression was significantly correlated with a poor prognosis in breast cancer patients. The results of immunohistochemistry, western blot assay, and qRT-PCR proved that NKAP was highly expressed in breast cancer tissues compared with paraneoplastic tissues. In addition, qRT-PCR results showed that high expression of NKAP was significantly correlated with the larger tumor size and higher TNM stage. Moreover, knockdown of NKAP significantly inhibited the proliferation, migration, and enhanced drug sensitivity of MDA-MB-231 and SK-BR-3 cells. NKAP is highly expressed in breast cancer tissues, and its high expression is closely associated with poor prognosis. NKAP also promotes proliferation, migration, and inhibits drug sensitivity of breast cancer cells.
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Srinagesh, Hrishikesh K. , Zhang, Amy, Grunwald, Michael R, Connor, Matthew P, Kota, Vamsi, Boccucci, Jacob , Ulrickson, M., Pradeep, Roshini , Hill, L, Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Sandhu, Karamjeet , Gordillo, Christian , Chen, Evan C., Lin, Chenyu, Kopmar, Noam E. , Majhail, Navneet S. , Lee, C F, Bobillo, Silvina Odstrcil, Park, Jae H, Valtis, Yannis K. , Solh, Melhem M, Guzowski, Caitlin, Vasu, Sumithira, Tan, Virginia, McCauley, Ross , Sasine, Joshua , Tang, Kevin, Kk, Miller, Sutherland, Katherine C. , Mohty, Razan , Jamy, Omer , Hoeg, Rasmus T., Logan, Aaron, Stock, Wendy A, Schwartz, Marc S., Byrd, Kenneth, Bachanova, Veronika, Tracy, Sean , Yaghmour, George , Gatell, Vivian Irizarry , Jackson, Clayton, Dholaria, Bhagirathbhai, O'Dwyer, Kristen M, Moore, Jozal , Aldoss, Ibrahim, Shah, B. D., Oliai, Caspian , Muffly, Lori, Grunwald, Michael R. , Kota, Vamsi , Bachanová, Veronika , Muffly, Lori , Hill, LaQuisa C. , Zhang, Amy , Connor, Matthew P. , Zhang, Amy , Grunwald, Michael , Connor, Matthew , Kota, Vamsi , Ulrickson, Matthew , Pradeep, Roshini , Hill, LaQuisa C , Advani, Anjali S , Reshef, Ran , Luskin, Marlise R , Chen, Evan , Lin, Chenyu , Cassaday, Ryan D , Kopmar, Noam E , Majhail, Navneet S , Battiwalla, Minoo , Strickland, Stephen Anthony , Lee, Catherine J , Odstrcil Bobillo, Silvina , Hilal, Talal , Faramand, Rawan , Leonard, Jessica T , Wang, Eunice S. , Sasine, Joshua , Sutherland, Katherine , Daunov, Michael , Jamy, Omer , Dykes, Kaitlyn C , Logan, Aaron C , Othman, Tamer , Stock, Wendy , Yalniz, Fevzi , Bachanova, Veronika , Irizarry Gatell, Vivian M , Oluwole, Olalekan O , Dholaria, Bhagirathbhai R , O'Dwyer, Kristin , Moore, Jozal , Roloff, Gregory W , Frey, Noelle V , Shah, Bijal , Oliai, Caspian H , Muffly, Lori , Gupta, Vishal , Ulrickson, Matthew L. , Tsai, Stephanie, Advani, Anjali S. , Reshef, Ran , Lin, Chenyu , Cassaday, Ryan D. , Battiwalla, Minoo , Bobillo, María Silvina Odstrcil , Hilal, Talal , Park, Jae H. , Faramand, Rawan , Solh, Melhem , Vasu, Sumithira , Daunov, Michael , Kumaran, Muthu Sendhil , Hoeg, Rasmus T. , Dykes, Kaitlyn C. , Othman, Tamer , Stock, Wendy , Byrd, Kenneth, Yalniz, Fevzi , Jackson, Clayton W., Oluwole, Olalekan O. , Dholaria, Bhagirathbhai , Roloff, Gregory W. , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood | February 5, 2026 | Volume: 147 | Issue: 17 | Pages: 2011-2017

10.1182/blood.2025031734 | PMID 41643192 Get It

Abstract In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.